First Affiliated Hospital Xi'an Jiaotong University
Clinical trials sponsored by First Affiliated Hospital Xi'an Jiaotong University, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Heart signal test could spot valve disease faster Results expected Sep 2026 (estimated)
- Bile acid pill may shield against statin blood sugar side effect Results expected Nov 2026 (estimated)
- New CMV prevention drug could be safer for kidney transplant patients Results expected Nov 2026 (estimated)
- Can we predict psoriasis relapse after biologics? a new study digs into the clues. Results expected Dec 2026 (estimated)
- Blood fat clues could flag hidden heart rhythm risk Results expected Jan 2027 (estimated)
-
Can an immunotherapy combo turn inoperable gallbladder cancer into a surgical success?
Disease control Not yet recruitingThis phase II trial is testing whether adding an experimental immunotherapy drug called AK112 to a standard chemotherapy regimen (gemcitabine, cisplatin, and albumin-bound paclitaxel) can shrink locally advanced gallbladder tumors enough to allow surgery. Adults with gallbladder …
Phase 2 • Sponsor: First Affiliated Hospital Xi'an Jiaotong University • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Clot-Busting heart procedure put to the test in massive new trial
Disease control Not yet recruitingThis study tests whether removing blood clots from heart arteries during emergency treatment can improve long-term heart health. About 6,760 adults having a severe heart attack will be randomly assigned to get standard care or standard care plus clot removal. Researchers will tra…
Sponsor: First Affiliated Hospital Xi'an Jiaotong University • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New drug duo aims to slash myeloma relapse after transplant
Disease control Not yet recruitingThis study tests whether adding thiotepa to the standard melphalan treatment before a stem cell transplant can lower the chance of multiple myeloma coming back within a year. It includes 204 adults aged 18-70 whose cancer was not fully cleared by prior therapy. Participants are r…
Sponsor: First Affiliated Hospital Xi'an Jiaotong University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Experimental Dual-Targeting T-Cell therapy takes on tough lymphomas
Disease control Not yet recruitingThis early-phase trial will test a new type of immune cell therapy called bispecific AbTCR T-cells in 3 adults with relapsed or refractory B-cell lymphoma (including diffuse large B-cell, follicular, and Burkitt lymphoma). The cells are designed to target two proteins (CD19 and C…
Early phase 1 • Sponsor: First Affiliated Hospital Xi'an Jiaotong University • Aim: Disease control
Last updated Jun 26, 2026 17:44 UTC
-
Heart signal test could spot valve disease faster
Diagnosis Not yet recruitingThis study aims to see if a new method using electrical and mechanical signals from the heart can accurately diagnose valvular heart disease. Researchers will recruit 1,300 adults with and without valve problems to compare the new test against standard echocardiography. If it wor…
Sponsor: First Affiliated Hospital Xi'an Jiaotong University • Aim: Diagnosis
Last updated Jun 27, 2026 12:37 UTC